PDF(Pubmed)
Abstract：
UNASSIGNED: EUS tissue acquisition (EUS-TA) is the standard diagnostic method for solid pancreatic lesions (SPLs); however, there are few reports on EUS-TA results for SPLs ≤10 mm. Furthermore, given the recent advent of fine-needle biopsy, the current diagnostic accuracy of EUS-TA for SPLs ≤10 mm is unknown. This study aimed to evaluate the diagnostic accuracy and efficacy of EUS-TA for SPLs ≤10 mm.
UNASSIGNED: We retrospectively analyzed the data of 109 patients with SPLs ≤10 mm who underwent EUS-TA. All patients underwent rapid on-site specimen evaluation.
UNASSIGNED: The median tumor diameter was 8 mm (range, 2.5-10 mm), and the technical success rate was 99.1% (108/109). Adverse events were observed in 3 patients (2.8%). The diagnostic performance was as follows: sensitivity, 90.1% (64/71); specificity, 97.3% (36/37); accuracy, 92.6% (100/108); positive predictive value, 98.5% (64/65); and negative predictive value, 83.7% (36/43). Multivariate analysis revealed that the number of punctures (odds ratio, 7.03; 95% confidence interval, 1.32-37.5; P = 0.023) and tumor type (odds ratio, 11.90; 95% confidence interval, 1.38-102.0; P = 0.024) were independent risk factors for inaccurate EUS-TA results. The diagnostic accuracy of EUS-TA for pancreatic ductal adenocarcinoma was 87.5% (14/16). No EUS-TA-related needle-tract seeding was observed in patients with pancreatic ductal adenocarcinoma during the observation period.
UNASSIGNED: EUS-TA for SPLs ≤10 mm showed adequate diagnostic accuracy and was safe for use with rapid on-site specimen evaluation in all cases.
UNASSIGNED: We retrospectively analyzed the data of 109 patients with SPLs ≤10 mm who underwent EUS-TA. All patients underwent rapid on-site specimen evaluation.
UNASSIGNED: The median tumor diameter was 8 mm (range, 2.5-10 mm), and the technical success rate was 99.1% (108/109). Adverse events were observed in 3 patients (2.8%). The diagnostic performance was as follows: sensitivity, 90.1% (64/71); specificity, 97.3% (36/37); accuracy, 92.6% (100/108); positive predictive value, 98.5% (64/65); and negative predictive value, 83.7% (36/43). Multivariate analysis revealed that the number of punctures (odds ratio, 7.03; 95% confidence interval, 1.32-37.5; P = 0.023) and tumor type (odds ratio, 11.90; 95% confidence interval, 1.38-102.0; P = 0.024) were independent risk factors for inaccurate EUS-TA results. The diagnostic accuracy of EUS-TA for pancreatic ductal adenocarcinoma was 87.5% (14/16). No EUS-TA-related needle-tract seeding was observed in patients with pancreatic ductal adenocarcinoma during the observation period.
UNASSIGNED: EUS-TA for SPLs ≤10 mm showed adequate diagnostic accuracy and was safe for use with rapid on-site specimen evaluation in all cases.
摘要：
■EUS组织采集（EUS-TA）是胰腺实性病变（SPL）的标准诊断方法；但是，很少有关于SPL≤10mm的EUS-TA结果的报告。此外，鉴于最近出现的细针活检，目前EUS-TA对SPL≤10mm的诊断准确性未知.本研究旨在评估EUS-TA对≤10mm的SPL的诊断准确性和有效性。
■我们回顾性分析了109例SPLs≤10mm患者接受EUS-TA的数据。所有患者均接受快速现场标本评估。
■中位肿瘤直径为8mm（范围，2.5-10mm),技术成功率为99.1%(108/109)。在3例患者中观察到不良事件（2.8％）。诊断性能如下：灵敏度，90.1%(64/71)；特异性，97.3%（36/37）；准确度，92.6%(100/108)；阳性预测值，98.5%(64/65)；阴性预测值，83.7%（36/43）。多变量分析显示，穿刺次数(赔率比，7.03；95%置信区间，1.32-37.5；P=0.023）和肿瘤类型（比值比，11.90；95%置信区间，1.38-102.0；P=0.024）是EUS-TA结果不准确的独立危险因素。EUS-TA对胰腺导管腺癌的诊断准确率为87.5%(14/16)。在观察期间，胰腺导管腺癌患者未观察到EUS-TA相关的针道播种。
■对于≤10mm的SPL，EUS-TA显示出足够的诊断准确性，并且在所有情况下都可以安全使用，可进行快速现场样本评估。
■我们回顾性分析了109例SPLs≤10mm患者接受EUS-TA的数据。所有患者均接受快速现场标本评估。
■中位肿瘤直径为8mm（范围，2.5-10mm),技术成功率为99.1%(108/109)。在3例患者中观察到不良事件（2.8％）。诊断性能如下：灵敏度，90.1%(64/71)；特异性，97.3%（36/37）；准确度，92.6%(100/108)；阳性预测值，98.5%(64/65)；阴性预测值，83.7%（36/43）。多变量分析显示，穿刺次数(赔率比，7.03；95%置信区间，1.32-37.5；P=0.023）和肿瘤类型（比值比，11.90；95%置信区间，1.38-102.0；P=0.024）是EUS-TA结果不准确的独立危险因素。EUS-TA对胰腺导管腺癌的诊断准确率为87.5%(14/16)。在观察期间，胰腺导管腺癌患者未观察到EUS-TA相关的针道播种。
■对于≤10mm的SPL，EUS-TA显示出足够的诊断准确性，并且在所有情况下都可以安全使用，可进行快速现场样本评估。
